Merck, a leading science and technology company, today announced the appointment of David Weinreich, MD, MBA, as Global Head of R&D and Chief Medical Officer for its Healthcare business sector.

默克公司，一家领先的科技公司，今天宣布任命大卫·温里希医学博士、工商管理硕士为医疗保健业务部门的全球研发主管兼首席医务官。

Weinreich is a highly-regarded biopharma leader with extensive experience and a proven track record in R&D. He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career. In addition, Weinreich has founded multiple companies and served as a venture capitalist, board member, and biotech CEO.

温赖希是一位备受推崇的生物制药领域领导者，在研发方面拥有丰富的经验和经过验证的成功记录。在超过20年的职业生涯中，他成功领导了全球范围内跨多个治疗领域的15种获批药物的开发。此外，温赖希还创立了多家公司，并曾担任风险投资家、董事会成员和生物技术公司首席执行官。

Weinreich joins Merck from Foresite Labs & Foresite Capital Management LLC, where he served as an Operating Partner and Senior Advisor. His previous experience includes: Executive Vice President, Head, Global Clinical Development at Regeneron; Corporate Senior Vice President, Head, Global Development Specialty Medicine at Bayer; and Executive Medical Director, Global Product Area Leader (Angiogenesis) at Amgen..

温赖希从Foresite Labs和Foresite Capital Management LLC加入默克，他曾担任运营合伙人和高级顾问。他之前的经验包括：Regeneron执行副总裁、全球临床开发负责人；拜耳公司高级副总裁、全球开发专科药物负责人；以及安进公司的执行医学总监、全球产品领域领导者（血管生成）。

“Scientific innovation is the engine that drives everything we do to transform patient care,” said Danny Bar Zohar, MD, Member of the Executive Board of Merck, and CEO Healthcare. “In David, we have a leader with a unique combination of deep scientific expertise, immense experience in drug development and successfully bringing drugs to the finish line, and global perspective—along with the clarity and boldness to shape a next-generation R&D strategy.

“科学创新是我们为转变患者护理所做的一切的驱动力，”默克执行董事会成员兼医疗保健首席执行官Danny Bar Zohar博士说道，“在David身上，我们拥有一个具备深厚科学专业知识、丰富药物开发经验并成功将药物推向市场、全球视野的领导者——他还拥有塑造下一代研发战略所需的清晰思路与果敢。”

His appointment marks an exciting step forward as we work to bring more medicines to more patients, faster.”.

他的任命标志着我们为更多患者更快地带来更多的药物迈出了令人兴奋的一步。

As Global Head of R&D and Chief Medical Officer, Weinreich will lead Research and Development for the Healthcare business sector of Merck, including Medical Affairs. Weinreich brings to Merck an exceptional record of success in leading early-stage and late-stage development, with leadership responsibility in achieving approvals across the globe for multiple therapies and indications.

作为全球研发主管兼首席医学官，温赖希将领导默克医疗保健业务领域的研发工作，包括医学事务。温赖希在早期和后期开发方面取得了卓越的成功记录，并在全球范围内为多种疗法和适应症的获批承担了领导责任，这些经验将为默克带来重要价值。

He has extensive experience in shaping R&D strategies that deliver meaningful value to patients and drive sustainable growth for future innovation investments. He also has effectively managed large and complex pipelines and global R&D teams..

他在制定为患者提供有意义的价值并推动未来创新投资可持续增长的研发战略方面拥有丰富的经验。他还有效管理了大型且复杂的研发管线以及全球研发团队。

“Joining Merck at such a pivotal moment in its growth journey offers a rare opportunity to lead scientific innovation with the potential to have a profound impact on patients’ lives,” said Dr. Weinreich. “This is an organization with a strong legacy, deep scientific capabilities, and a clear commitment to delivering meaningful value where it’s needed most.

“在默克如此关键的增长时刻加入，提供了一个难得的机会来领导科学创新，有可能对患者的生活产生深远的影响，”温赖希博士说。“这是一个拥有强大传承、深厚科学能力以及明确承诺的组织，在最需要的地方提供有意义的价值。”

I look forward to working with teams around the world to advance a clear R&D strategy grounded in urgency, collaboration, and purpose.”.

我期待与世界各地的团队合作，推动一项基于紧迫性、协作性和目标性的明确研发战略。”

Weinreich will be based in Billerica, Massachusetts at the company’s Research and Development site.

温赖希将常驻马萨诸塞州比勒里卡的公司研发基地。